Nicholas M. Pachuda

Gid Bio Inc. develops next-generation cellular therapies for degenerative musculoskeletal, dermal, and organ specific diseases. The company is based in Louisville, CO. The technology uniquely isolates and concentrates a cellular implant that is administered by injection in a physician's office under image guidance. The company has been granted two CPT Class III codes, a step toward Medicare reimbursement. Gid Bio's SVF-2 technology and point-of-care therapy harness the innate power of a patient's own stromal cells. The company was founded in 2010 by Adam J. Katz, G. Patrick Maxwell, Ramon Llull, J. William Futrell. The CEO is William W. Cimino.

BioRez, Inc. engages in the design and development of resorbable polymer scaffold technology. The firm offers a device that is suited for tendon, ligament, and other soft tissue injuries. The company was founded by Cato T. Laurencin and Joseph W. Reilly in 2008 and is headquartered in New Haven, CT.

Gid Bio Inc. develops next-generation cellular therapies for degenerative musculoskeletal, dermal, and organ specific diseases. The company is based in Louisville, CO. The technology uniquely isolates and concentrates a cellular implant that is administered by injection in a physician's office under image guidance. The company has been granted two CPT Class III codes, a step toward Medicare reimbursement. Gid Bio's SVF-2 technology and point-of-care therapy harness the innate power of a patient's own stromal cells. The company was founded in 2010 by Adam J. Katz, G. Patrick Maxwell, Ramon Llull, J. William Futrell. The CEO is William W. Cimino.

BioRez, Inc. engages in the design and development of resorbable polymer scaffold technology. The firm offers a device that is suited for tendon, ligament, and other soft tissue injuries. The company was founded by Cato T. Laurencin and Joseph W. Reilly in 2008 and is headquartered in New Haven, CT.

BioRez, Inc. engages in the design and development of resorbable polymer scaffold technology. The firm offers a device that is suited for tendon, ligament, and other soft tissue injuries. The company was founded by Cato T. Laurencin and Joseph W. Reilly in 2008 and is headquartered in New Haven, CT.

BioRez, Inc. engages in the design and development of resorbable polymer scaffold technology. The firm offers a device that is suited for tendon, ligament, and other soft tissue injuries. The company was founded by Cato T. Laurencin and Joseph W. Reilly in 2008 and is headquartered in New Haven, CT.

Gid Bio Inc. develops next-generation cellular therapies for degenerative musculoskeletal, dermal, and organ specific diseases. The company is based in Louisville, CO. The technology uniquely isolates and concentrates a cellular implant that is administered by injection in a physician's office under image guidance. The company has been granted two CPT Class III codes, a step toward Medicare reimbursement. Gid Bio's SVF-2 technology and point-of-care therapy harness the innate power of a patient's own stromal cells. The company was founded in 2010 by Adam J. Katz, G. Patrick Maxwell, Ramon Llull, J. William Futrell. The CEO is William W. Cimino.

Gid Bio Inc. develops next-generation cellular therapies for degenerative musculoskeletal, dermal, and organ specific diseases. The company is based in Louisville, CO. The technology uniquely isolates and concentrates a cellular implant that is administered by injection in a physician's office under image guidance. The company has been granted two CPT Class III codes, a step toward Medicare reimbursement. Gid Bio's SVF-2 technology and point-of-care therapy harness the innate power of a patient's own stromal cells. The company was founded in 2010 by Adam J. Katz, G. Patrick Maxwell, Ramon Llull, J. William Futrell. The CEO is William W. Cimino.